- Email: [email protected]
P3-058: Development of the subjective memory complaints questionnaire (SMCQ)
T534
Poster Presentations P3:
personnel including primary care physicians and other health professionals were the most common referral source. Future goals include doubling the patient volume annually, achieving more minority referrals, and increasing research referral volume to address the overarching goal of enhanced clinical trials volume. New Patient Characteristics 2007 Mean Age (SD) % Female % Caucasian Mean MMSE score (SD)
76 (⫾10) 59% 94% 20.6 (⫾7)
scores were significantly correlated with the scores on CMCQ, SIRQD, and the tests in the CERAD-N (P⬍.01). The results of factor analyses confirmed that the SMCQ consisted of SMC for general memory (SMCQ-G) and for everyday memory (SMCQ-E). The SMCQ score well discriminated nondemented elderly without dementia from those with dementia (P⬍.01). The AUC value of the SMCQ was .84, indicating that it had high diagnostic ability. Conclusions: The SMCQ was found to be a brief, reliable, and valid questionnaire for evaluating SMC and screening dementia. It may be particularly useful for evaluating cognition of elderly subjects when reliable informants are not available. P3-059
Primary Diagnosis Probable and Possible AD Mild Cognitive Impairment Lewy Body Dementia and Frontotemporal Dementia Other
P3-058
60% 8% 5% 17%
DEVELOPMENT OF THE SUBJECTIVE MEMORY COMPLAINTS QUESTIONNAIRE (SMCQ)
Jong Chul Youn1, Ki Woong Kim2, Dong Young Lee3, Jin Hyeong Jhoo4, Seok Bum Lee2, Joon Hyuk Park2, Eun Ae Choi2, Jin Yeong Choe2, Ji Won Jeong2, Il Han Choo3, Jong Inn Woo3, 1 Kyunggi Provincial Hospital for the Elderly, Yongin, Republic of Korea; 2Seoul National University Bundang Hospital, Sungnam, Republic of Korea; 3Seoul National University Hospital, Seoul, Republic of Korea; 4Kangwon National University Hospital, Chuncheon, Republic of Korea. Contact e-mail: [email protected] Background: Although several instruments for evaluating subjective memory complaints has been used, psychometric properties of it were rarely tested. This study aimed to evaluate the psychometric properties of subjective memory complaint questionnaire (SMCQ). Methods: 1651 elderly subjects including 692 randomly selected subjects living in the Metropolitan areas of Seongnam and Seoul in the Republic of Korea were recruited. The reliabilities of the 14-item SMCQ were evaluated by testing its internal consistency and test-retest reliabilities. Pearson correlation analyses were performed to assess the concurrent validity of the SMCQ and the CAMDEX Memory Complaint Questionnaire (CMCQ), Seoul Informant Report Questionnaire for Dementia (SIRQD) and CERAD neuropsychological battery (CERAD-N). Confirmatory factor analysis was used to evaluate the construct validity. The discriminant validity of SMCQ was also tested. Receiver operator characteristic (ROC) curve analyses were performed to evaluate the diagnostic ability of the SMCQ for dementia detection. Results: Cronbach’s alpha coefficient and intraclass correlation coefficient was .864. and .828 (P⬍.001), respectively. The SMCQ
COMBINATION OF CSF PEDF, HAPTOGLOBIN AND TAU MEASUREMENTS IMPROVES ALZHEIMER DIAGNOSIS
Jean-Daniel D. Abraham1, Sophie Pawlowsky1, Sandra Cobo1, Marie-Clotilde C. Mondon1, Guillaume Vicat1, Nicolas Salvetat1, Jacques Touchon2, Bernard Michel3, Jean-Michel M. Verdier3, Jeannette Fareh1, Chantal Mourton-Gilles1, 1CNRS FRE3009 Bio-Rad SysDiag, Montpellier, France; 2Neurology Department, Gui de Chauliac Hospital, Montpellier, France; 3INSERM UM2 EPHE U710, Montpellier 2 University, Montpellier, France. Contact e-mail: [email protected] Background: To improve Alzheimer Disease (AD) diagnosis, proteomic studies investigated protein implication in pathological processes such as inflammation, apoptosis or oxidative stress. Among these, Verdier and coll. (patent application) analysed cererospinal fluids (CSFs) from 95 patients suffering from different dementia using protein profiling (2D-Gel). They identified two potential AD biomarkers, pigment epithelium-derived factor (PEDF) and haptoglobin (Hp). Both proteins were shown to have anti-oxidative functions and could have potential diagnostic properties for AD. To study the discriminative potential of PEDF and Hp in AD diagnosis, we developed specific antibodies and corresponding ELISA assays and evaluated PEDF and Hp concentrations in CSF from a series of Alzheimer and non Alzheimer patients. Methods: Hp purified from sera and E.coli-expressed recombinant PEDF were used as immuogens to generate murine monoclonal antibodies and rabbit polyclonal sera. These antibodies were used to develop specific and sensitive ELISA assays which were used to analyse CSF from Alzheimer patients (AD, n⫽27), from non-Alzheimer dement patients (NAD, n⫽30) including fronto-temporal and vascular dementia (respectively FTD, n⫽15; VaD, n⫽12), and non dement patients (ND, n⫽27). Tau concentrations were evaluated with INNOTEST hTau, Innogenetics Corp., according to the manufacturer’s protocol. Results: Monoclonal and polyclonal antibodies detect specifically native proteins in CSF and brain extracts. ELISA tests allow CSF PEDF (min: 9ng/ml; max: 80ng/ml) and Hp (min: 130ng/ml; max: 6g/ml) measurements. Evaluation of single marker concentration fails to discriminate the studied patient groups. However, combination of PEDF and Hp to Tau, using mROC (multiple Receiving Operating Curves) analyses, clearly showed diagnosis improvement, especially for FTD and VaD versus AD. Conclusions: The current pilot study shows the potential role of PEDF and haptoglobin in AD diagnosis and highlights the probable different contribution of vascular and oxidative mechanisms in AD from FTD and VaD physiopathologies. Larger clinical trials need to be performed in order to confirm these preliminary study. P3-060
CEREBROSPINAL FLUID MARKERS IN DEMENTIA WITH LEWY BODIES (DLB) IN COMPARISON WITH ALZHEIMERⴕS DISEASE (AD)
Souhad Al Faqih, Swaida Health Center, Sweida, Syrian Arab Republic. Contact e-mail: [email protected]
Poster Presentations P3:
personnel including primary care physicians and other health professionals were the most common referral source. Future goals include doubling the patient volume annually, achieving more minority referrals, and increasing research referral volume to address the overarching goal of enhanced clinical trials volume. New Patient Characteristics 2007 Mean Age (SD) % Female % Caucasian Mean MMSE score (SD)
76 (⫾10) 59% 94% 20.6 (⫾7)
scores were significantly correlated with the scores on CMCQ, SIRQD, and the tests in the CERAD-N (P⬍.01). The results of factor analyses confirmed that the SMCQ consisted of SMC for general memory (SMCQ-G) and for everyday memory (SMCQ-E). The SMCQ score well discriminated nondemented elderly without dementia from those with dementia (P⬍.01). The AUC value of the SMCQ was .84, indicating that it had high diagnostic ability. Conclusions: The SMCQ was found to be a brief, reliable, and valid questionnaire for evaluating SMC and screening dementia. It may be particularly useful for evaluating cognition of elderly subjects when reliable informants are not available. P3-059
Primary Diagnosis Probable and Possible AD Mild Cognitive Impairment Lewy Body Dementia and Frontotemporal Dementia Other
P3-058
60% 8% 5% 17%
DEVELOPMENT OF THE SUBJECTIVE MEMORY COMPLAINTS QUESTIONNAIRE (SMCQ)
Jong Chul Youn1, Ki Woong Kim2, Dong Young Lee3, Jin Hyeong Jhoo4, Seok Bum Lee2, Joon Hyuk Park2, Eun Ae Choi2, Jin Yeong Choe2, Ji Won Jeong2, Il Han Choo3, Jong Inn Woo3, 1 Kyunggi Provincial Hospital for the Elderly, Yongin, Republic of Korea; 2Seoul National University Bundang Hospital, Sungnam, Republic of Korea; 3Seoul National University Hospital, Seoul, Republic of Korea; 4Kangwon National University Hospital, Chuncheon, Republic of Korea. Contact e-mail: [email protected] Background: Although several instruments for evaluating subjective memory complaints has been used, psychometric properties of it were rarely tested. This study aimed to evaluate the psychometric properties of subjective memory complaint questionnaire (SMCQ). Methods: 1651 elderly subjects including 692 randomly selected subjects living in the Metropolitan areas of Seongnam and Seoul in the Republic of Korea were recruited. The reliabilities of the 14-item SMCQ were evaluated by testing its internal consistency and test-retest reliabilities. Pearson correlation analyses were performed to assess the concurrent validity of the SMCQ and the CAMDEX Memory Complaint Questionnaire (CMCQ), Seoul Informant Report Questionnaire for Dementia (SIRQD) and CERAD neuropsychological battery (CERAD-N). Confirmatory factor analysis was used to evaluate the construct validity. The discriminant validity of SMCQ was also tested. Receiver operator characteristic (ROC) curve analyses were performed to evaluate the diagnostic ability of the SMCQ for dementia detection. Results: Cronbach’s alpha coefficient and intraclass correlation coefficient was .864. and .828 (P⬍.001), respectively. The SMCQ
COMBINATION OF CSF PEDF, HAPTOGLOBIN AND TAU MEASUREMENTS IMPROVES ALZHEIMER DIAGNOSIS
Jean-Daniel D. Abraham1, Sophie Pawlowsky1, Sandra Cobo1, Marie-Clotilde C. Mondon1, Guillaume Vicat1, Nicolas Salvetat1, Jacques Touchon2, Bernard Michel3, Jean-Michel M. Verdier3, Jeannette Fareh1, Chantal Mourton-Gilles1, 1CNRS FRE3009 Bio-Rad SysDiag, Montpellier, France; 2Neurology Department, Gui de Chauliac Hospital, Montpellier, France; 3INSERM UM2 EPHE U710, Montpellier 2 University, Montpellier, France. Contact e-mail: [email protected] Background: To improve Alzheimer Disease (AD) diagnosis, proteomic studies investigated protein implication in pathological processes such as inflammation, apoptosis or oxidative stress. Among these, Verdier and coll. (patent application) analysed cererospinal fluids (CSFs) from 95 patients suffering from different dementia using protein profiling (2D-Gel). They identified two potential AD biomarkers, pigment epithelium-derived factor (PEDF) and haptoglobin (Hp). Both proteins were shown to have anti-oxidative functions and could have potential diagnostic properties for AD. To study the discriminative potential of PEDF and Hp in AD diagnosis, we developed specific antibodies and corresponding ELISA assays and evaluated PEDF and Hp concentrations in CSF from a series of Alzheimer and non Alzheimer patients. Methods: Hp purified from sera and E.coli-expressed recombinant PEDF were used as immuogens to generate murine monoclonal antibodies and rabbit polyclonal sera. These antibodies were used to develop specific and sensitive ELISA assays which were used to analyse CSF from Alzheimer patients (AD, n⫽27), from non-Alzheimer dement patients (NAD, n⫽30) including fronto-temporal and vascular dementia (respectively FTD, n⫽15; VaD, n⫽12), and non dement patients (ND, n⫽27). Tau concentrations were evaluated with INNOTEST hTau, Innogenetics Corp., according to the manufacturer’s protocol. Results: Monoclonal and polyclonal antibodies detect specifically native proteins in CSF and brain extracts. ELISA tests allow CSF PEDF (min: 9ng/ml; max: 80ng/ml) and Hp (min: 130ng/ml; max: 6g/ml) measurements. Evaluation of single marker concentration fails to discriminate the studied patient groups. However, combination of PEDF and Hp to Tau, using mROC (multiple Receiving Operating Curves) analyses, clearly showed diagnosis improvement, especially for FTD and VaD versus AD. Conclusions: The current pilot study shows the potential role of PEDF and haptoglobin in AD diagnosis and highlights the probable different contribution of vascular and oxidative mechanisms in AD from FTD and VaD physiopathologies. Larger clinical trials need to be performed in order to confirm these preliminary study. P3-060
CEREBROSPINAL FLUID MARKERS IN DEMENTIA WITH LEWY BODIES (DLB) IN COMPARISON WITH ALZHEIMERⴕS DISEASE (AD)
Souhad Al Faqih, Swaida Health Center, Sweida, Syrian Arab Republic. Contact e-mail: [email protected]